Companies in #Oncology

AbbVie (NYSE: ABBV) is a global, research-driven biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. AbbVie develops and commercializes therapeutics across immunology (Humira, Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta, Epkinly), neuroscience (Vraylar, Duopa), and aesthetics (Botox, Juvederm), with growing investments in oncology, neuroscience, and eye care.

Discovers and develops antibody therapeutics using high-throughput single cell analysis and microfluidic platforms for complex transmembrane proteins, bispecifics, and ADCs. Reported strong menopause medicine efficacy data (Phase 2) in August 2026.

Agios Pharmaceuticals is a biopharmaceutical company focused on developing therapies for rare diseases, including pyruvate kinase (PK) activation and other cellular metabolism targets. The company markets PYRUKYND® (mitapivat) for hemolytic anemia in adults with PK deficiency and is exploring additional indications in thalassemia and sickle cell disease.

Akari Therapeutics, Plc (NASDAQ: AKTX) is an oncology biotechnology company headquartered in Tampa, Florida, developing antibody-drug conjugates (ADCs) built on a novel PH1 RNA spliceosome-modulating payload that disrupts RNA splicing in cancer cells and triggers immune-mediated tumor killing.

Akesobio is a Chinese clinical-stage biopharmaceutical company developing innovative antibodies for oncology and inflammatory diseases, including the PD-1xVEGF bispecific ivonescimab partnered with Summit Therapeutics.

Clinical-stage cell therapy company developing next-generation CAR-T cell therapies for solid tumors.

Ascletis Pharma is a China-based clinical-stage biopharmaceutical company developing small-molecule and peptide therapeutics for viral diseases, metabolic diseases (including obesity), and oncology. Its lead metabolic candidate ASC36_35 FDC targets GLP-1/GIP agonism.

Targeted oncology company developing therapies for ocular and urologic oncology indications using a novel virus-like drug conjugate (VDC) platform.

Avenda Health is a ai-enabled medical devices company. See today's news for the latest developments.

Bayer (ETR: BAYN) is a diversified life sciences company headquartered in Leverkusen, Germany.

BeOne Medicines is a global oncology company that discovers and develops innovative medicines intended to improve the lives of patients worldwide. The company markets BRUKINSA (zanubrutinib), a BTK inhibitor approved for B-cell malignancies.

Precision molecular diagnostics company (NASDAQ: BLLN) that quantifies biology at the single-molecule level to detect and measure DNA molecules. Its molecular counting platform underpins UNITY Complete, a non-invasive prenatal screen assessing fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw, and the Northstar liquid biopsy franchise: Northstar Select reports tumor mutations from blood, while Northstar Response is a methylation-based assay quantifying cancer burden in real time without a tissue biopsy. Incorporated in 2016 and publicly listed in November 2025, the company grew revenue more than 60% year over year in Q2 2026.

Beijing-headquartered global biotechnology company (SSE: 688796, HKEX: 02315) providing integrated antibody drug development solutions through proprietary gene-editing platforms and RenMab/RenNano antibody discovery engines.

BioNTech is a public biotechnology company developing mRNA-based medicines, cancer immunotherapies, infectious-disease vaccines, and antibody-based oncology programs.

Clinical-stage biotech developing oncology therapies for non-small cell lung cancer, with a lead Tagrisso-chasing EGFR-targeted program.

Boulevard Bio is a Deerfield Management-backed biotech launched in 2026, co-founded by Georg Schett and Frank Nestle, focused on immune reset therapeutics for autoimmune disease starting with autoimmune kidney disorders.

Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company with a strong oncology franchise (Opdivo, Yervoy, Reblozyl, Pomalyst, Empliciti), hematology, cardiovascular (Eliquis), and immunology (Sotyktu, Zeposia, deucravacitinib). BMS is investing in cell therapy, radiopharmaceuticals, and next-generation immuno-oncology platforms.

Global biopharmaceutical company (NYSE: BMY) focused on oncology, hematology, immunology, cardiovascular, neuroscience and fibrotic disease; marketed assets include Opdivo (nivolumab), Yervoy, Revlimid, Eliquis (apixaban with Pfizer), Pomalyst, Sprycel, Reblozyl, Sotyktu, deucravacitinib and the cardio-failure drug Camzyos; major acquisitions: Celgene ($74B, 2019), MyoKardia ($13B, 2020), Turning Point Therapeutics ($4.1B, 2022), Karuna Therapeutics ($14B, 2024), RayzeBio ($4.1B, 2024).

Global mid-sized Contract Research Organization (CRO) operating in 23 countries, providing patient-centric clinical trial solutions for biopharma innovators across oncology, rare disease, and cell & gene therapy programs.

Caris Life Sciences is a leading patient-centric next-generation AI TechBio company and precision medicine pioneer. The company operates the Caris Assure and Caris Discovery platforms for molecular profiling of cancer patients, enabling oncologists to match patients to targeted therapies and clinical trials.

Global healthcare media and marketing agency specializing in pharmaceutical and life sciences brand strategy, media planning, and medical communications. A WPP company.

Clinical-stage biopharmaceutical company (NASDAQ: CNTX) advancing medicines for solid tumors, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody. In August 2026 the company discontinued its bispecific program to extend its cash runway into 2027.

CRISPR Therapeutics is a Swiss-American biopharmaceutical company pioneering CRISPR/Cas9 gene editing therapies for serious diseases. The company developed Casgevy (exagamglogene autotemcel), the first CRISPR-based gene therapy approved by the FDA and EMA for sickle cell disease and transfusion-dependent beta thalassemia. The company is advancing a broad pipeline spanning hemoglobinopathies, oncology, autoimmune diseases, and in vivo gene editing programs.

Clinical-stage biopharmaceutical company developing Immuno-STAT biologics designed to selectively engage disease-relevant T cells for cancer and autoimmune disease; its CUE-221 candidate for chronic spontaneous urticaria hit its Phase 2 primary endpoint in September 2026.

Biotechnology company specializing in antibody-drug conjugate (ADC) technology for oncology. Entered a $1B collaboration with Genentech to develop next-generation ADCs targeting drug-resistance mechanisms in cancer.

Japanese pharmaceutical company with a focus on neuroscience and oncology, known for developing the Alzheimer's treatment Leqembi (lecanemab) in partnership with Biogen.

Elevar Therapeutics is a private oncology-focused biopharmaceutical company developing and commercializing cancer therapies, including programs in liver cancer and other solid tumors.

Eli Lilly and Company is a major global pharmaceutical company with a broad portfolio spanning diabetes/obesity, oncology, neuroscience, immunology, and rare diseases. Its GLP-1 franchise (Mounjaro/tirzepatide, Zepbound) and the oral GLP-1 candidate orforglipron are reshaping obesity care. Lilly has been the most aggressive large-pharma dealmaker of the past decade, completing more biotech buyouts than any other top-12 pharma by revenue, with 10 acquisitions in 2026 alone accounting for roughly half of pharma's total M&A capacity (~$25B+ committed).

Clinical-stage biotech in Solana Beach, CA developing precision therapeutics for oncology and fibrotic diseases. Raised $132.5M in Series C.

Fate Therapeutics is a clinical-stage biopharmaceutical company pioneering off-the-shelf NK and T-cell cancer immunotherapies derived from induced pluripotent stem cells (iPSCs). Its pipeline includes FT596 (CD19 CAR-NK), FT819 (CD19 CAR-T), and FT522 (CD19 + IL-15 CAR-NK) in hematologic malignancies and autoimmune disease.

Formation Bio is an AI-native drug development company building a clinical-stage pipeline through in-licensing and asset acquisition, with a focus on using technology and AI to accelerate clinical trial execution. In early 2026, the company launched a new subsidiary, Kenmare Bio, to develop a miR-124 inhibitor licensed from a Chinese partner for inflammatory diseases.

Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.

Generate Biomedicines, Inc. (NASDAQ: GENB) is a clinical-stage generative-biology company headquartered in Somerville, Massachusetts, using machine learning and its Generate Platform to program novel protein therapeutics; it went public in February 2026 and is a Flagship Pioneering-founded company whose lead programs span immunology (GB-0895 anti-TSLP) and oncology (GB-4362, GB-5267).

Gilead Sciences (NASDAQ: GILD) is a Foster City, California-based biopharmaceutical company with leadership in HIV (Biktarvy, Descovy), viral hepatitis (Sovaldi, Harvoni, Epclusa), and a growing oncology franchise (Trodelvy, Yescarta, Tecartus).

Family-owned German pharmaceutical company focused on pain management and adjacent therapies; in September 2026 it agreed to acquire Bayer's oncology drug Stivarga for up to 375 million euros.

Services: Pharmaceutical medicines, vaccines, consumer healthcare; specialty medicines in HIV, oncology, respiratory; vaccines for hepatitis, HPV, meningitis.

R&D-driven pharmaceutical company focused on new drug development, synthesis, and manufacturing based in Chengdu, China.

Hansoh Pharmaceutical Group is a China-based biopharmaceutical company with marketed products and development programs across oncology, central nervous system disorders, anti-infectives, metabolic disease, and autoimmune disease.

HCW Biologics is a clinical-stage biopharmaceutical company developing novel immunotherapies for chronic, low-grade inflammation and related diseases. Its pipeline includes HCW9302, an injectable IL-2 fusion protein complex in clinical trials for alopecia areata; HCW11-018b, a tetra-valent T-cell engager; and multifunctional fusion molecules combining cytokines with checkpoint blockade. The company also develops reagents for NK-cell and CAR-therapy production under licensing arrangements with partners such as Wugen and WY Biotech.

Shanghai Henlius Biotech is a Chinese biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality biosimilars and innovative oncology biologics, with a portfolio marketed in China, Europe, and emerging markets.

HUTCHMED is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapeutics and immunotherapies for cancer and immunological diseases. The company has licensed its dual-action KRAS/EGFR cancer drug to GSK for $110 million upfront.

Huyabio International is a clinical-stage biopharmaceutical company developing novel small molecule oncology therapeutics. Lead program HBI-8000 (tucidinostat) is an HDAC inhibitor that has demonstrated Phase 3 success in melanoma and is approved in China for multiple oncology indications.

AI-driven small molecule drug discovery company whose Enchant platform combines generative models such as NeuralPLexer with high-throughput experimentation to design therapeutics; partnered with AbbVie and Revolution Medicines.

Chinese cell therapy company developing BCMA-targeted CAR-T therapies, led by equecabtagene autoleucel (CT103A) for relapsed/refractory multiple myeloma, with an in vivo CAR-T pipeline.

Incyte is a oncology / inflammation company. See today's news for the latest developments.

Protein-engineering and single-domain antibody platform company developing therapeutic candidates for oncology and rare diseases. Nasdaq: INBX.

Chinese biotech developing innovative biologics including monoclonal antibodies and bispecifics for oncology, ophthalmology, and autoimmune diseases.

Insilico Medicine is an end-to-end generative artificial intelligence-driven drug discovery company connecting biology, chemistry, and clinical trials analysis.

Medtech company developing NIO Laser Imaging System, using stimulated Raman histology for intraoperative fresh tissue imaging, plus AI-based image analysis for cancer detection.

Commercial-stage biopharmaceutical company (NASDAQ: IOVA) developing and commercializing autologous tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its lead product Amtagvi (lifileucel) is an individualized T cell therapy approved for previously treated advanced or unresectable or metastatic melanoma, marketed alongside Proleukin (interleukin-2). The pipeline extends lifileucel into cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma, with next-generation programs including LN-145, IOV-2001, IOV-4001, and IOV-3001. Q2 2026 product revenue of $99.3 million (up from $59 million a year earlier) powered a roughly 43% single-day gain and a new 52-week high in August 2026.

Ipsen is a global specialty biopharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of in-market products including Dysport (botulinum toxin), Somatuline (lanreotide), and Onivyde (irinotecan). The company is advancing a refreshed R&D pipeline in 2026 with multiple Phase 3 readouts planned, alongside a new wave of partnership-led discovery deals.

Jazz Pharmaceuticals is a global biopharmaceutical company focused on neuroscience and oncology, with a commercial portfolio that includes Xywav (low-sodium oxybate), Epidiolex (cannabidiol), and Zepzelca (lurbinectedin). The company markets Zepzelca in the U.S. under license from PharmaMar and is facing renewed questions about the drug's accelerated approval in small cell lung cancer after a confirmatory Phase 3 trial failed to meet its primary endpoint.

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation operating through two business segments: Innovative Medicine and MedTech. It is one of the world's largest and most diversified healthcare companies, with products spanning oncology, immunology, neuroscience, cardiovascular, and surgical technologies.

New cell therapy licensing company founded by Ying Huang (former Legend Biotech CMO). Focused on licensing Asian cell therapy assets into Western markets with a $250M target raise.

Kelun-Biotech (Sichuan Kelun-Biotech Biopharmaceutical) is a biologics / adc company. See today's news for the latest developments.

Kriya Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for common chronic diseases of high unmet need, including Type 1 diabetes, obesity, oncology, and rare diseases. Unlike most AAV gene therapy companies that focus on rare diseases with small patient populations, Kriya's strategic differentiation is targeting chronic conditions with much larger patient populations. Kriya operates its own in-house, large-scale GMP manufacturing facilities for gene therapy at its Research Triangle Park (Durham, North Carolina) headquarters — a notable strategic departure from the typical gene therapy CDMO-out-source model. The company was founded in 2019 by Shankar Ramaswamy, M.D. (former senior partner at McKinsey and former CEO of Axovant) and has raised over $600M in venture funding. Kriya was selected in June 2026 for the FDA PreCheck Pilot Program for its Durham, NC manufacturing facility.

Kyowa Kirin Co., Ltd. is a Japanese specialty pharmaceutical and biotechnology company under the Kirin Holdings group, focused on developing innovative antibody-based drugs for cancer, kidney disease, immune system diseases, and rare diseases. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. Kyowa Kirin is the Japan-based parent of Kyowa Kirin, Inc. (the US subsidiary), and operates as a research-driven biopharma with multiple approved biologics including poteligeo (mogamulizumab, for cutaneous T-cell lymphoma) and Crysvita (burosumab, for X-linked hypophosphatemia). The company announced a $530M biologics manufacturing facility in Sanford, North Carolina in June 2024 — its first US manufacturing site — which was selected in June 2026 for the FDA PreCheck Pilot Program. Kyowa Kirin's US subsidiary (KKNA) operates the Sanford facility and supports the company's clinical and commercial biologics pipeline including rocatinlimab for atopic dermatitis.

Legend Biotech is a global clinical-stage biopharmaceutical company pioneering the development of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and solid tumors. Its lead product, CARVYKTI® (ciltacabtagene autoleucel), is approved for relapsed/refractory multiple myeloma and is co-developed with Johnson & Johnson.

Lunai Bioworks (NASDAQ: LNAI), formerly Renovaro Inc. (renamed August 2025), is an AI-driven precision medicine and biodefense company headquartered in Los Angeles. The company operates through three segments — RENB (cell therapy vaccines), BioSymetrics (AI drug discovery), and RENC (CNS) — developing genetically modified allogeneic dendritic cell therapeutic vaccines including RENB-DC11 for solid tumors (primarily pancreatic) and RENB-DC20 for breast cancer, plus an AI multi-omics platform for early cancer detection and recurrence monitoring. In May 2026 Lunai completed a $20M preferred issuance to acquire CNS delivery and neurotherapeutic IP, and in July 2026 it launched a foundation-funded Parkinson's and rare epilepsy AI discovery collaboration with BrainStorm Therapeutics. The company is also pursuing federal biodefense contracts. Since May 2026 it has pursued a naked-short-selling fraud suit under Regulation SHO and RICO, filing a First Amended Complaint on August 4, 2026 naming ten defendants including three FINRA-registered broker-dealers.

Italian pharmaceutical company specializing in biologics, CDMO services, and specialty pharmaceuticals. Active in European and global markets with recent expansion into obesity therapeutics via GLP-1 licensing deals.

Myricx Bio is a UK-based biotech developing a pipeline of antibody-drug conjugates (ADCs) for cancer using its proprietary N-myristoyltransferase inhibitor (NMTi) payload chemistry. The company raised a GBP 90M Series A and is being acquired by Novartis for up to $1.5B.

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world, developing innovative medicines in therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology.

Orca Bio is a clinical-stage cell therapy company developing high-precision, allogeneic cell therapies for cancer and autoimmune diseases.

Orionis Biosciences is a life sciences company pioneering conditionally active immunotherapies (A-Kines) and molecular glue drug discovery (AlloGlues) for cancer and immunology. The company has research collaborations with Novartis and Genentech/Roche, and is advancing internal programs in oncology and immunology.

Cell-specific targeted protein degraders (TPD2) and stabilizers (TPS2) built on antibody conjugation, including ORM-5029 for HER2-expressing solid tumors.

AI-enabled precision oncology biotech that uses multimodal patient data, biological modeling, and machine learning to identify Phase 1 cancer drugs for specific patient subgroups, partnering with pharma for clinical trial design and drug repositioning.

Perimeter Medical Imaging AI is a commercial-stage medical imaging company developing AI-driven optical coherence tomography (OCT) for breast cancer surgery and other surgical oncology applications.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. The company develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.

Phanes Therapeutics is a clinical-stage biotechnology company focused on innovative drug discovery and development in oncology. Recently expanded its clinical trial collaboration with Merck to evaluate spevatamig in combination with KEYTRUDA for biliary tract cancer.

Quanterix is a life-sciences company commercializing single-molecule array (Simoa) technology for ultra-sensitive protein biomarker detection, with platforms including the HD-X and SR-X instruments and the SP-X planar-array system. It operates in neurology, oncology, immunology, and inflammation, selling instruments, assays, and contract research services to academic, government, and pharmaceutical laboratories. Founded by David Walt in 2007 and listed on Nasdaq in 2017, the company acquired Akoya Biosciences in 2025 to add multiplexed spatial biology. In Q2 2026 it reported revenue up 34% year over year to $32.9 million while cutting its full-year 2026 revenue outlook.

Radiopharm Theranostics is a clinical-stage radiopharmaceutical company developing paired diagnostic imaging and therapeutic candidates across several validated oncology targets, spanning peptides, small molecules and monoclonal antibodies radiolabelled with medical isotopes. Its pipeline pairs imaging agents such as 18F-RAD101 for recurrent brain metastases and Ga-68-RAD301 for pancreatic ductal adenocarcinoma with therapeutic assets including 177Lu-RAD202 in HER2-positive solid tumours and the B7-H3-targeted 177Lu-Betabart (RV-01) developed through a joint venture with MD Anderson Cancer Center. The company, which trades on both the ASX and Nasdaq, has a strategic agreement with Lantheus Holdings and isotope supply arrangements covering Lutetium-177 and Terbium-161.

RedHill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases, with a pipeline spanning oncology and pulmonary indications. It commercialized Talicia (H. pylori eradication) and Aemcolo (travelers' diarrhea) in the U.S. and, on August 31, 2026, announced the divestiture of its Talicia business to a subsidiary of Apotex Health for $18 million upfront plus up to $35 million in worldwide net-sales milestones, using the proceeds to fund U.S. pipeline expansion. Pipeline candidates include opaganib, RHB-107 (upamostat), RHB-104, RHB-102 (Bekinda), and RHB-204 (Phase 3 for pulmonary Mycobacterium avium complex disease).

Redx Pharma is a clinical-stage biopharmaceutical company developing precision medicines targeting oncology and fibrotic diseases, with a pipeline of small molecule inhibitors of oncogenic and fibrotic pathways.

Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers and other difficult-to-treat tumors.

Clinical-stage biopharmaceutical company that builds and launches modular subsidiary companies (Vants) developing transformative therapies across immunology, neurology, oncology, and rare disease.

Sail Biomedicines is a Flagship Pioneering-backed in vivo CAR-T biotech engineering mRNA-encoded therapeutics to treat autoimmune disease and cancer. The company is developing programmable medicines that instruct the body to produce its own therapeutic proteins inside target cells.

Sandoz is a global leader in generic pharmaceuticals and biosimilars, spun off from Novartis in 2023 to focus on off-patent medicines across immunology, oncology, infectious diseases, and metabolic disorders.

Sanofi (NASDAQ: SNY; Euronext: SAN) is a global biopharmaceutical company with major franchises in immunology (Dupixent, partnered with Regeneron), vaccines (Beyfortus, Fluzone, Dengvaxia), rare disease (Genzyme-legacy Pompe, Fabry, MS), and a growing oncology pipeline. Sanofi has been reshaping its R&D portfolio toward immunology and rare disease while spinning off its consumer health unit.

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead product, apitegromab, is being developed for spinal muscular atrophy (SMA).

Scribe Therapeutics is a clinical-stage gene editing company developing next-generation CRISPR-based therapies for serious genetic diseases.

Hong Kong-listed (HKEX: 1177) pharmaceutical conglomerate specializing in biopharmaceuticals, modern Chinese medicine, and chemical medicines. Therapeutic focus on hepatobiliary, oncology, cardiovascular, and respiratory diseases.

Global CNS-focused biopharmaceutical company developing and commercialising treatments for epilepsy, sleep disorders and oncology, including cenobamate (XCOPRI/Ontozry).

Skyhawk Therapeutics is a clinical-stage biotechnology company developing small-molecule RNA splicing modulators using its proprietary SkySTAR platform, with programs in neurology, oncology, autoimmune, and fibrotic diseases.

Sunshine Biopharma is a pharmaceutical company that develops and commercializes generic and specialty prescription drugs in Canada and the United States, alongside an early-stage research pipeline in antivirals and oncology. Its research programs include SBFM-PL4, a protease inhibitor being developed for SARS coronavirus infections, and K1.1 mRNA, a lipid nanoparticle candidate for liver cancer. The commercial side of the business markets a portfolio of generic prescription medications spanning osteoporosis, cardiovascular, hypertension, anti-inflammatory, diabetes, oncology, gastroenterology, dermatology, women's health and central nervous system indications, and the company also sells consumer health products including the Essential 9 amino-acid capsules and Calcium-Vitamin D supplements. The company is headquartered in Fort Lauderdale, Florida and trades on the Nasdaq Capital Market, where it has undertaken two reverse stock splits within a year — a 1-for-10 split effective June 1, 2026, and a written-consent authorization on September 15, 2026 for a further split of up to 1-for-20 — in both cases to maintain compliance with the exchange's minimum bid price requirement.

Radiopharmaceutical company developing imaging and therapeutic products for oncology, including PSMA-PET imaging agent Illuccix and the late-stage kidney cancer imaging agent TLX250-CDx; acquiring ITM Isotope Technologies Munich to add a therapeutic pipeline and isotope supply network.

Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. Its platform collects and analyzes clinical and molecular data to enable physicians and researchers to make data-driven decisions in oncology, cardiology, and other disease areas.

Tubulis is a biotechnology company developing a new generation of antibody-drug conjugates (ADCs) for the treatment of cancer. Its proprietary platforms — Tub-tag, P5 conjugation, and Topoisomerase-I inhibitor payloads — enable the design of highly stable, targeted ADCs with improved therapeutic index. In May 2026, Gilead Sciences completed the acquisition of Tubulis for up to $5 billion ($3.15B cash upfront + $1.85B milestones).

Clinical-stage oncology company developing tumor-targeting therapeutics for solid tumors using its PIP agent platform that targets integrins on solid tumor tissue.

Clinical-stage precision oncology company developing next-generation FGFR inhibitors, including oral dabogratinib for skeletal dysplasia and urologic cancers, using its proprietary SNÅP discovery platform.

AI-driven drug discovery company applying generative models and machine learning to small molecule and biologics design.

Zymeworks is a clinical-stage biotechnology company developing multifunctional biotherapeutics for difficult-to-treat cancers. The company's platforms include Azymetric (bispecific antibodies) and EFECT (immune-effector modulation), and it is advancing multiple wholly-owned and partnered oncology candidates. In 2026 Zymeworks expanded its pipeline through the near-$1B acquisition of Theravance Biopharma, adding a lung-disease drug candidate plus royalty streams.